{"id":"W4304084160","doi":"10.1016/j.annonc.2022.09.159","title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":447,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Merck Sharp and Dohme; University of Illinois at Urbana-Champaign; National Institutes of Health; Karolinska Institutet; Clovis Oncology; National Institute for Health and Care Research; Seagen; Cilag; Puma Biotechnology; NRG Oncology; Les Laboratories Pierre Fabre; Institut Bergonié; Amgen; Rush University; University of Pennsylvania; Genentech; Institut Gustave-Roussy; Merck KGaA; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; School of Medicine, Indiana University; European Commission; Sanofi; Genomic Health; Ochsner Health; MSD; GlaxoSmithKline; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Olaparib; Internal medicine; Oncology; Placebo; Hazard ratio; Breast cancer; Confidence interval; Cancer; Pathology; Biology; Polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001322768,0.0001457178,0.0007256502,0.0002635102,0.0000337631,0.000003039407,0.0001448846,0.00009032188,0.0002654778],"category_scores_gemma":[0.00003559704,0.0001106884,0.00005070327,0.0004214112,0.0001564071,0.00007534803,0.00005925496,0.0004098042,3.947908e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001394147,"about_ca_system_score_gemma":0.0004614925,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008189053,"about_ca_topic_score_gemma":0.002275627,"domain_scores_codex":[0.9976158,0.0007556461,0.000676829,0.0002785733,0.0003914986,0.0002816682],"domain_scores_gemma":[0.9989129,0.0002369156,0.000431712,0.0002519558,0.0001128772,0.00005360201],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.330544,0.009670939,0.5943536,0.00004634524,0.0001663634,0.000170235,0.004526933,0.0002344075,0.001174843,0.0002747054,0.00045372,0.05838398],"study_design_scores_gemma":[0.2346171,0.00885249,0.7555746,0.00005728867,0.00002972113,0.00001134131,0.0001162159,0.00003866259,0.00007931422,0.0001735447,0.0003596836,0.0000900234],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954574,0.0002857129,0.000003627388,0.002257954,0.0002517224,0.0009612534,0.00064087,0.000004703174,0.0001367572],"genre_scores_gemma":[0.9982827,0.0004124288,0.00002421728,0.0008998717,0.00008193007,0.0002141222,0.00005174121,0.0000164003,0.00001659287],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1612211,"threshold_uncertainty_score":0.9984155,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03810809554894744,"score_gpt":0.3551060294228056,"score_spread":0.3169979338738582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}